Literature DB >> 28807235

Stereotactic ablative radiation therapy in renal cell carcinoma: From oligometastatic to localized disease.

Filippo Alongi1, Stefano Arcangeli2, Luca Triggiani3, Rosario Mazzola4, Michela Buglione di Monale E Bastia3, Sergio Fersino5, Anna Baiguini3, Barbara Alicja Jereczek-Fossa6, Stefano Maria Magrini3.   

Abstract

Renal Cell Carcinoma (RCC) has historically been considered a radioresistant cancer, and radiotherapy was usually delivered with a palliative goal. Stereotactic ablative radiotherapy (SABR) allows the delivery of high doses on small treatment volumes in a safe and effective way, thus opening the doors to new applicationsof radiotherapy both in the treatment of the primary and oligometastasic disease. Aim of the current review is to explore the state of art of SABR in the therapeutic approach to RCC.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Oligometastases; Renal cell carcinoma; SABR; Stereotactic radiotherapy

Mesh：

Year:  2017        PMID： 28807235     DOI： 10.1016/j.critrevonc.2017.07.004

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN： 1040-8428            Impact factor:   6.312


  6 in total

1.  Radiotherapy for oligometastatic cancer: a survey among radiation oncologists of Lombardy (AIRO-Lombardy), Italy.

Authors:  Barbara Alicja Jereczek-Fossa; Barbara Bortolato; Marianna Alessandra Gerardi; Samantha Dicuonzo; Virginia Maria Arienti; Stefania Berlinghieri; Stefano Bracelli; Michela Buglione; Mariangela Caputo; Gianpiero Catalano; Luigi Franco Cazzaniga; Luigi De Cicco; Nadia Di Muzio; Francesco Romeo Filippone; Andrei Fodor; Davide Franceschini; Paolo Frata; Stefania Gottardo; Giovanni Battista Ivaldi; Antonio Laudati; Stefano Maria Magrini; Elisa Mantero; Ilaria Meaglia; Sara Morlino; Mauro Palazzi; Fabio Piccoli; Paola Romanelli; Marta Scorsetti; Flavia Serafini; Luciano Scandolaro; Riccardo Valdagni; Roberto Orecchia; Paolo Antognoni
Journal:  Radiol Med       Date:  2018-12-15       Impact factor: 3.469

2.  Efficacy and safety of tyrosine kinase inhibitors alone or in combination with radiation therapy for metastatic renal cell carcinoma: A protocol for evidence-based systematic review and Bayesian network meta-analysis.

Authors:  Shihua Wang; Weihua Jin; Changqing Jiang; Yiwen Zhang; Kaiwen Deng
Journal:  Medicine (Baltimore)       Date:  2021-08-20       Impact factor: 1.817

3.  GUROPA survey: genito-urinary radiation oncology prescription attitudes.

Authors:  Sergio Fersino; Stefano Arcangeli; Barbara Alicja Jereczek-Fossa; Rolando D'Angelillo; Filippi Bertoni; Giuseppe Roberto D'Agostino; Luca Triggiani; Renzo Corvò; Stefano Maria Magrini; Filippo Alongi
Journal:  Radiol Med       Date:  2018-07-13       Impact factor: 3.469

Review 4.  Oligometastasis and local ablation in the era of systemic targeted and immunotherapy.

Authors:  Rosario Mazzola; Barbara Alicja Jereczek-Fossa; Davide Franceschini; Slavisa Tubin; Andrea Riccardo Filippi; Maria Tolia; Andrea Lancia; Giuseppe Minniti; Stefanie Corradini; Stefano Arcangeli; Marta Scorsetti; Filippo Alongi
Journal:  Radiat Oncol       Date:  2020-05-04       Impact factor: 3.481

5.  A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma.

Authors:  Rohann J M Correa; Belal Ahmad; Andrew Warner; Craig Johnson; Mary J MacKenzie; Stephen E Pautler; Glenn S Bauman; George B Rodrigues; Alexander V Louie
Journal:  Radiat Oncol       Date:  2018-03-20       Impact factor: 3.481

6.  Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study.

Authors:  Natalia Dengina; Timur Mitin; Sergey Gamayunov; Sufia Safina; Yuliya Kreinina; Ilya Tsimafeyeu
Journal:  ESMO Open       Date:  2019-10-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.